Advertisement

Topics

Clinical Trials About "Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma" RSS

17:59 EDT 15th July 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma" on BioPortfolio

We have published hundreds of Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma news stories on BioPortfolio along with dozens of Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma Clinical Trials and PubMed Articles about Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma Companies in our database. You can also find out about relevant Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma Drugs and Medications on this site too.

Showing "Rationale Cytogenetic Risk Stratification Imaging Flow Cytometry Multiple" Clinical Trials 1–25 of 35,000+

Extremely Relevant

Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma

A pioneer study demonstrated a proof of concept for IS-FISH with the new ISX technology. This state of the art technology has been recently acquired by the CHU of Amiens. In the present study the investigators want to establish a workflow for simultaneous immunostaining and characterization of FISH cytogenetic pathological signals with the imaging flow cytometer ISX, such as chromosomic gains, losses and translocations in multiple myeloma (MM). The gold standard technology for ...


Stratified Therapy Based on Cytogenetic and Molecular Abnormality and MRD Levels for AML

Risk stratification-directed therapy based on cytogenetic and molecular abnormality for acute myeloid leukemia (AML) is well accepted and benefits patients' survival. However, neither every patient with low risk factors abtains better survival, nor all high risk patients experience worse outcome. Lots of data have shown the important role of minimal residual disease (MRD) in prognostic prediction. In this study, we perform risk stratification based on not only Cytogenetic and M...

STAT4 in Multiple Sclerosis by PCR and Flow Cytometry

1. To determine the level of STAT4 expression in different cases of multiple sclerosis and its relation to disease severity . 2. compare the sensitivity and specificity of STAT4 levels using both PCR and flow cytometry.


Relevant

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

RATIONALE: Gathering health information about patients with acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best treatment. PURPOSE: This research study is developing a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia.

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

RATIONALE: Lenalidomide and dexamethasone may stop the growth of multiple myeloma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works with or without dexamethasone in treating patients with newly diagnosed multiple myeloma.

VEGF Trap in Treating Patients With Stage II or Stage III Multiple Myeloma That Has Relapsed or Not Responded to Previous Treatment

RATIONALE: VEGF Trap may be able to carry cancer-killing substances directly to multiple myeloma cells. It may also stop the growth of multiple myeloma by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment.

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with relapsed or refractory multiple myeloma.

Evaluation of ClearLLab Leukemia and Lymphoma Panels

Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematological diseases work-up.

Imaging Procedures in Women With a Genetic Risk For Breast Cancer

RATIONALE: Imaging procedures, such as MRI and PET scans, may improve the ability to detect cancer in women who have a genetic risk for breast cancer. PURPOSE: Screening study of MRI and PET to detect cancer in women who have a genetic risk for breast cancer.

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may be an effective treatment for multiple myeloma. PURPOSE: This phase II trial is studying the side e...

Lenalidomide and CCI-779 in Treating Patients With Previously Treated Multiple Myeloma

RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. CCI-779 may also stop the growth of cancer cells by blocking some of the enzymes needed for their growth. Giving lenalidomide together with CCI-779 may kill more cancer cells. PURPOSE: This phase I trial is study...

DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.

Interest of Flow Cytometry for the Diagnosis, the Follow up and Specific Immunotherapy (SIT) Arrest of Hymenoptera Venom Allergy

The aim of this study is to show that flow cytometry can be an accurate tool to help physicians regarding the diagnosis, the SIT decision and the SIT arrest of hymenoptera venom allergy. 75 patients having a story of reaction to hymenoptera venom will be selected for this trial. Blood samples will be analyzed at: inclusion visit, Week 1 visit, Week 3 visit, Week 10 and Week 21 visit.

The Molecular Characterization of Multiple Myeloma at Relapse

Multiple myeloma (MM) is an incurable cancer. The disease can often be brought to a halt with chemotherapy which in younger patients is accompanied by stem cell transplantation. But the disease relapses almost invariably. Cytogenetic changes in the myeloma cells can serve as prognostic markers. Accordingly, 25% of the patients show changes associated with a prognosis so poor that they should probably receive experimental treatment right from the start. Nevertheless, a part of t...

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

RATIONALE: MS-275 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving MS-275 together with GM-CSF may be an effective treatment for myelodysplastic syndrome and acute myeloid leukemia. PURPOSE: This phase II trial is studying how well giving MS-275 together with GM-C...

Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma. PURPOSE: This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma.

Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma

RATIONALE: Cytogenetic tests may help predict how cancer will respond to treatment and allow doctors to plan more effective therapy. PURPOSE: This diagnostic trial is studying genetic differences in patients with treated and untreated acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, or multiple myeloma.

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

RATIONALE: Sorafenib and everolimus may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of sorafenib and everolimus and to see how well they work in treating patients with relapsed or refractory non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma.

MODIFY (Mds DIagnosis Flow cYtometry)

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterized by cytopenia(s), dysplasia in one or more major myeloid cell lines and progression to acute leukemia. Morphological analysis of peripheral blood (PB) and bone marrow (BM) remains the cornerstone of the diagnosis. Preliminary studies identified Flow Cytometry (FC) markers on red cells, platelets and circulating leukocytes that are expressed differently in MDS and in controls. Ho...

Tumor-Infiltrating Lymphocytes in Treating Patients With Persistent or Recurrent B-Cell Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma After a Previous Donor Stem Cell Transplant

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy using tumor-infiltrating lymphocytes, may stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This phase I trial is studying the side effects and how well tumor-infiltrating lymphocytes work in treating patients with persistent or recurrent B-cell non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, or multiple myeloma after a previous dono...

Risk Stratification Using PET in HCM

The overall rationale is to reduce the risk of sudden cardiac death in individuals with hypertrophic cardiomyopathy (HCM). The novel approach of this study is to correlate Positron Emission Tomography (PET) findings to ventricular arrhythmias detected by the implantable cardioverter defibrillator (ICD). This could potentially lead to an improved risk stratification of HCM patients.

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of myelodysplastic cells, either by killing the cells or by stopping them from dividing. Tretinoin and decitabine may help myelodysplastic cells become more like normal cells, and to grow and spread more slowly. Giving decitabine together with tretinoin may be an effective treatment for myelodysplastic syndromes. PURPOSE: This phase I/II trial is studying the side effects and b...

Multiple Myeloma Minimal Residual Disease

Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease

Unlock the Cell: Castleman's Disease Flow Cytometry Study

The purpose of this study is to study stained Castleman's Disease lymph nodes and perform flow cytometry and cell culture experiments on Castleman Disease blood samples to determine which cellular pathways and immune cell types are driving the disease.

Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival

Objectives To demonstrate that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a surrogate for overall survival and thus an early read-out for drug efficacy Study design Surrogate endpoint trial to establish that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a surrogate for overall survival


More From BioPortfolio on "Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement